West Announces Second-Quarter 2019 Results and Announces an Increase to Fourth-Quarter 2019 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
West Pharma (WST) Tops Q2 EPS by 17c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
July 25, 2019 6:08 AM EDTWest Pharma (NYSE: WST) reported Q2 EPS of $0.89, $0.17 better than the analyst estimate of $0.72. Revenue for the quarter came in at $469.7 million versus the consensus estimate of $460.4 million.
Net sales of $469.7 million grew 4.9%, organic sales growth was 8.1%; sales from a recent acquisition contributed an additional 20 basis points of growth.Reported-diluted EPS of $0.88 increased 17%.Adjusted-diluted EPS of $0.89 increased 27%.Company is raising full-year 2019 net sales guidance to a new range of between $1.810 billion and $1.825 billion.Company is raising full-year 2019 adjusted-diluted EPS guidance to a... More